Related Experiment Video
Updated: May 24, 2026
10:38
Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
Published on: November 22, 2019
CXCR4 expression in prostate cancer progenitor cells.
Anna Dubrovska1, Jimmy Elliott, Richard J Salamone
1The Scripps Research Institute, La Jolla, California, United States of America. anna.dubrovska@oncoray.de
Plos One
|February 24, 2012
Summary
Prostate cancer stem-like cells utilize the CXCR4/CXCL12 pathway for growth and survival. Targeting this pathway with AMD3100 alongside chemotherapy significantly improves tumor eradication.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Medicine
Background:
- Tumor progenitor cells contribute to chemotherapy resistance and cancer relapse.
- The role of prostate cancer progenitors in metastasis remains largely unknown.
- The CXCR4/CXCL12 axis is crucial for tumor cell dissemination.
Purpose of the Study:
- To investigate the role of the CXCR4/CXCL12 axis in prostate cancer stem-like cells.
- To evaluate the therapeutic potential of targeting this axis in prostate cancer.
Main Methods:
- Analysis of CXCR4/CXCL12 pathway activation in CD44(+)/CD133(+) prostate progenitor cells.
- Assessment of pathway effects on differentiation, adhesion, growth, and tumorigenicity.
- In vivo studies using prostate tumor xenografts in mice treated with AMD3100 and Taxotere.
Main Results:
- The CXCR4/CXCL12 pathway is active in prostate cancer stem-like cells.
- This pathway influences key cancer stem cell properties, including differentiation and tumorigenicity.
- Combination therapy with AMD3100 and Taxotere demonstrated superior tumor eradication compared to monotherapy.
Conclusions:
- The CXCR4/CXCL12 axis is vital for maintaining prostate cancer stem-like cells.
- Targeting prostate cancer stem-like cells with CXCR4 antagonists, in combination with chemotherapy, offers a promising therapeutic strategy.
